The U.S. Food and Drug Administration has granted accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously known as INO-3107, to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis. The approval is based on data from the RRP-001 study showing a complete response rate of 27%, defined as no surgical intervention required for 12 months post-treatment. Continued approval may be contingent on verification of clinical benefit in confirmatory studies, with a draft protocol expected by the end of 2026 and final alignment by mid-2027. VOCERYQ is approved in combination with CELLECTRA 5PSP, the company's proprietary DNA medicine delivery device. The company expects to make the product available to order and ship in approximately 60 days, with full field deployment anticipated during the first quarter of 2027. Inovio Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative DNA medicines.
